The Life Sciences team advised Mariana Oncology Inc. on its oversubscribed $175 million Series B financing co-led by Deep Track Capital and Forbion, and included founding investors Atlas Venture, Access Biotechnology and RA Capital Management, as well as additional new investors Nextech Invest, Surveyor Capital (a Citadel company) and Eli Lilly and Company.
Proceeds from the financing will support the advancement of Mariana Oncology’s novel portfolio of precision, next-generation radiopharmaceuticals including its lead candidate, MC-339, as the company transitions into a clinical-stage organization.
Mariana Oncology is a fully integrated, next-generation radiopharmaceuticals company focused on pioneering a new class of targeted peptide-based radiopharmaceuticals.
The Goodwin team was led by Kingsley Taft, and included Joseph Jung Hyuk Yim, Stefanie Hartford, Amy Josselyn and GG Guckaya, with valuable contributions from Carolyn Nguyen, Neil Doogan, Scott Zilora, Joseph Coughlin and Kathy Georgian.
For more details, read the press release and article in Endpoints News.